The Patent Finder

Betta Pharmaceuticals Co., Ltd.

Also on record
Records under this name other than the patents Betta Pharmaceuticals Co., Ltd. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned. None of them is counted in the 11 patents it holds.

Showing 1 to 10 of 10 · Back to Betta Pharmaceuticals Co., Ltd.

PatentTitleStatus Expires Confidence
US 12,275,737Polymorphs of a Kinase Inhibitor, Pharmaceutical Compositions Containing Such a Compound, Preparation Methods, and Applications
Formerly held
In force
 · High confidence
In forceHigh confidence
US 11,365,196FGFR inhibitor and application thereof
Lapsed on the fee record
Ended Jun 21, 2026 · From the USPTO record
Lapsed on the fee recordEnded Jun 21, 2026From the USPTO record
US 8,742,138Compounds as hypoxia mimetics, and compositions and uses thereof
Formerly held
Lapsed on the fee record
Ended Jun 3, 2026 · From the USPTO record
Lapsed on the fee recordEnded Jun 3, 2026From the USPTO record
US 9,688,687Polymorphic forms of icotinib phosphate and uses thereof
Lapsed on the fee record
Ended Jun 27, 2025 · From the USPTO record
Lapsed on the fee recordEnded Jun 27, 2025From the USPTO record
US 9,617,257Fused pyridine derivatives useful as c-Met tyrosine kinase inhibitors
Lapsed on the fee record
Ended Apr 11, 2025 · From the USPTO record
Lapsed on the fee recordEnded Apr 11, 2025From the USPTO record
US 9,487,570Glucagon like peptide analogs, composition, and method of use
Lapsed on the fee record
Ended Nov 8, 2024 · From the USPTO record
Lapsed on the fee recordEnded Nov 8, 2024From the USPTO record
US 10,577,364Crystalline form of fused pyridine derivative's maleate and uses thereof
Lapsed on the fee record
Ended Mar 3, 2024 · From the USPTO record
Lapsed on the fee recordEnded Mar 3, 2024From the USPTO record
US 9,242,991Substituted fused heterocycles as c-Met tyrosine kinase inhibitors
Lapsed on the fee record
Ended Jan 26, 2024 · From the USPTO record
Lapsed on the fee recordEnded Jan 26, 2024From the USPTO record
US 10,059,688Protein tyrosine kinase modulators and methods of use
Lapsed on the fee record
Ended Aug 28, 2022 · From the USPTO record
Lapsed on the fee recordEnded Aug 28, 2022From the USPTO record
US 9,783,524Protein tyrosine kinase modulators and methods of use
Lapsed on the fee record
Ended Oct 10, 2021 · From the USPTO record
Lapsed on the fee recordEnded Oct 10, 2021From the USPTO record
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 16, 2026 · includes USPTO assignment & status data published Nov 16, 2026 and grant & fee data published Nov 10, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited